C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying o-glycosylation of FGFR2

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2096-2106

  Hung, Ji Shiang ^a,b   Huang, John ^b   Lin, Yo Chuen ^a   Huang, Miao Juei ^a   Lee, Po Huang ^b   Lai, Hong Shiee ^b   Liang, Jin Tung ^b   Huang, Min Chuan ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; Glycosylation; Receptor tyrosine kinase

Indexed keywords

CORE 1 BETA 1,3 GALACTOSYLTRANSFERASE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GALACTOSYLTRANSFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; C1GALT1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MODIFICATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CELL MOTION; COLON TUMOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; GLYCOSYLATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; COLONIC NEOPLASMS; FLOW CYTOMETRY; GALACTOSYLTRANSFERASES; GLYCOSYLATION; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; PHOSPHORYLATION; POLYSACCHARIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; UP-REGULATION;

EID: 84899505287     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1815     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
2. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK and Stephens RJ. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370(9582):143-152.
3. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J and Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101(19):1308-1324.
4. Tran DT and Ten Hagen KG. Mucin-type O-glycosylation during development. J Biol Chem. 2013; 288(10):6921- 6929.
5. Ten Hagen KG, Fritz TA and Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2003; 13(1):1R-16R.
6. Ju T and Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A. 2002; 99(26):16613-16618.
7. Tian E and Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj J. 2009; 26(3):325-334.
8. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L and Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/ TRAIL. Nat Med. 2007; 13(9):1070-1077.
9. Gill DJ, Tham KM, Chia J, Wang SC, Steentoft C, Clausen H, Bard-Chapeau EA and Bard FA. Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc Natl Acad Sci U S A. 2013; 110(34):E3152-3161.
10. Xia L, Ju T, Westmuckett A, An G, Ivanciu L, McDaniel JM, Lupu F, Cummings RD and McEver RP. Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. J Cell Biol. 2004; 164(3):451-459.
11. Kudo T, Sato T, Hagiwara K, Kozuma Y, Yamaguchi T, Ikehara Y, Hamada M, Matsumoto K, Ema M, Murata S, Ohkohchi N, Narimatsu H and Takahashi S. C1galt1-deficient mice exhibit thrombocytopenia due to abnormal terminal differentiation of megakaryocytes. Blood. 2013; 122(9):1649-1657.
12. Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, McDaniel JM, Sferra TJ, Turner JR, Chen H, Hansson GC, Braun J, et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest. 2011;121(4):1657-1666.
13. Cascio S, Farkas AM, Hughey RP and Finn OJ. Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. Oncotarget. 2013; 4(10):1686-1697.
14. Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, Hu RH and Huang MC. C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells via Modulating MET Glycosylation and Dimerization. Cancer Res. 2013; 73(17):5580-5590.
15. An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J and Xia L. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med. 2007; 204(6):1417-1429.
16. Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, Barrois M, Dessen P, Kagedal B, Benard J, Osinaga E and Raguenez G. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma. Clin Chem. 2006; 52(9):1701-1712.
17. Freire T, Berois N, Sonora C, Varangot M, Barrios E and Osinaga E. UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer. 2006; 119(6):1383-1388.
18. Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, Velculescu VE, et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci U S A. 2009; 106(31):12921-12925.
19. Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H and Zhu M. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer. 2010; 10:123.
20. Fuster MM and Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005; 5(7):526-542.
21. Yoo NJ, Kim MS and Lee SH. Absence of COSMC gene mutations in breast and colorectal carcinomas. APMIS. 2008; 116(2):154-155.
22. Ryder SD, Smith JA, Rhodes EG, Parker N and Rhodes JM. Proliferative responses of HT29 and Caco2 human colorectal cancer cells to a panel of lectins. Gastroenterology. 1994; 106(1):85-93.
23. Xia L and McEver RP. Targeted disruption of the gene encoding core 1 beta1-3-galactosyltransferase (T-synthase) causes embryonic lethality and defective angiogenesis in mice. Methods Enzymol. 2006; 416:314-331.
24. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K and Rhodes JM. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007; 282(1):773-781.
25. Matsuda Y, Ueda J and Ishiwata T. Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Patholog Res Int. 2012; 2012:574768.
26. Matsuda Y, Ishiwata T, Yamahatsu K, Kawahara K, Hagio M, Peng WX, Yamamoto T, Nakazawa N, Seya T, Ohaki Y and Naito Z. Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer. Cancer Lett. 2011; 309(2):209-219.
27. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-111.
28. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC and Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009; 8(10):806-823.
29. Hatch NE, Hudson M, Seto ML, Cunningham ML and Bothwell M. Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F. J Biol Chem. 2006; 281(37):27292-27305.
30. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, Gupta R, Bennett EP, Mandel U, Brunak S, Wandall HH, Levery SB, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 2013; 32(10):1478-1488.
31. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A and Rittenhouse-Olson K. Cancer vaccines and carbohydrate epitopes. Vaccine. 2011; 29(48):8802-8826.
32. Huang MC, Chen HY, Huang HC, Huang J, Liang JT, Shen TL, Lin NY, Ho CC, Cho IM and Hsu SM. C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene. 2006; 25(23):3267-3276.
33. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K and Narimatsu H. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A. 2005; 102(12):4572-4577.
34. Huang J, Che MI, Lin NY, Hung JS, Huang YT, Lin WC, Huang HC, Lee PH, Liang JT and Huang MC. The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK. Mol Carcinog. 2013.